 Allena Pharmaceuticals Inc NASDAQ: ALNA posted data from the first cohort of the Phase 2 trial Study 201 evaluating ALLN-346 for hyperuricemia and gout in advanced chronic kidney disease CKD. The data demonstrated a statistically significant reduction in serum uric acid sUA from baseline p 